Gammagard

Gammagard is an immunoglobulin-based drug manufactured by Baxter International. It is a brand of intravenous immunoglobulin.

Early experimental results from a small clinical trial in humans have shown hints that it may protect against the progression of Alzheimer's Disease.

In 2013 it failed a phase III clinical trial for Alzheimer's Disease.